Antipyrine test predicts pharmacodynamics in docetaxel and cisplatin combination chemotherapy

Lung Cancer

Volumn 49, Issue 2, 2005, Pages 245-251

  Nishio, Makoto ^a   Matsuda, Masanori ^a   Ohyanagi, Fumiyoshi ^a   Sato, Yukitohi ^a   Okumura, Sakae ^a   Tabata, Daisuke ^a   Morikawa, Akinobu ^a   Nakagawa, Ken ^a   Horai, Takeshi ^a  

^a CANCER INSTITUTE HOSPITAL   (Japan)

Author keywords

1 Acid glycoprotein; CYP3A4; Cytochrome P450; Docetaxel; Lung cancer

Indexed keywords

ALPHA1 GLYCOPROTEIN; CISPLATIN; CYTOCHROME P450; DOCETAXEL; PHENAZONE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE REGRESSION; NAUSEA; NEUTROPENIA; PREDICTION; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADENOCARCINOMA; ADOLESCENT; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIPYRINE; CARCINOMA, ADENOSQUAMOUS; CARCINOMA, LARGE CELL; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CYTOCHROME P-450 ENZYME SYSTEM; DISEASE PROGRESSION; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEUTROPENIA; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 22044435525     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2005.02.007     Document Type: Article

References (28)

1. Non-Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials Br Med J 311 1995 899 909
2. P.A. Bunn Jr. Treatment of advanced non-small-cell lung cancer with two-drug combinations J Clin Oncol 20 2002 3565 3567
3. V.A. Miller, and M.G. Kris Docetaxel (Taxotere) as a single agent and in combination chemotherapy for the treatment of patients with advanced non-small cell lung cancer Semin Oncol 27 2000 3 10
4. J.R. Rigas Docetaxel in stage III and IV non-small cell lung cancer Eur J Cancer 31A Suppl. 4 1995 S18 S20
5. J.H. Schiller, D. Harrington, and C.P. Belani Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
6. F. Fossella, J.R. Pereira, and J. von Pawel Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 Study Group J Clin Oncol 21 2003 3016 3024
7. K. Kubota, K. Watanabe, and H. Kunitoh Phase III randomized trial of docetaxel plus cisplatin versus vindesine plus cisplatin in patients with stage IV non-small-cell lung cancer: the Japanese Taxotere Lung Cancer Study Group J Clin Oncol 22 2004 254 261
8. N. Yamamoto, T. Tamura, and Y. Kamiya Correlation between docetaxel clearance and estimated cytochrome P450 activity by urinary metabolite of exogenous cortisol J Clin Oncol 18 2000 2301 2308
9. J. Hirth, P.B. Watkins, and M. Strawderman The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance Clin Cancer Res 6 2000 1255 1258
10. B.C. Goh, S.C. Lee, and L.Z. Wang Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies J Clin Oncol 20 2002 3683 3690
11. G. Engel, U. Hofmann, and H. Heidemann Antipyrine as a probe for human oxidative drug metabolism: identification of the cytochrome P450 enzymes catalyzing 4-hydroxyantipyrine, 3-hydroxymethylantipyrine, and norantipyrine formation Clin Pharmacol Ther 59 1996 613 623
12. E.S. Vesell The antipyrine test in clinical pharmacology: conceptions and misconceptions Clin Pharmacol Ther 26 1979 275 286
13. P. Spoelstra, M.W. Teunissen, and A.R. Janssens Antipyrine clearance and metabolite formation: the influence of liver volume and smoking Eur J Clin Invest 16 1986 321 327
14. S.A. Coverdale, J. Field, and G.C. Farrell How reversible is hepatic functional impairment in autoimmune hepatitis? J Gastroenterol Hepatol 18 2003 371 375
15. A. el-Yazigi, D.A. Raines, and F.A. Wahab Relationship between antipyrine metabolism and acetylation phenotype in health and chronic liver diseases J Clin Pharmacol 35 1995 615 621
16. G.C. Farrell, and L. Zaluzny Accuracy and clinical utility of simplified tests of antipyrine metabolism Br J Clin Pharmacol 18 1984 559 565
17. J.M. Scavone, D.J. Greenblatt, and G.T. Blyden Simplified approaches to the determination of antipyrine pharmacokinetic parameters Br J Clin Pharmacol 25 1988 695 699
18. D. Kadar, T. Inaba, and L. Endrenyi Comparative drug elimination capacity in man - glutethimide, amobarbital, antipyrine, and sulfinpyrazone Clin Pharmacol Ther 14 1973 552 560
19. E.S. Vesell, and J.G. Page Genetic control of dicumarol levels in man J Clin Invest 47 1968 2657 2663
20. E.E. Werk Jr., K. Thrasher, and L.J. Sholiton Cortisol production in epileptic patients treated with diphenylhydantoin Clin Pharmacol Ther 12 1971 698 703
21. W.M. Awni, and L.J. Bakker Antipyrine, indocyanine green, and lorazepam determined in plasma by high-pressure liquid chromatography Clin Chem 35 1989 2124 2126
22. World Health Organization WHO handbook for reporting results of cancer treatment 1979 World Health Organization, WHO Offset Publication Geneva, Switzerland p. 48
23. R. Bruno, D. Hille, and A. Riva Population pharmacokinetics/ pharmacodynamics of docetaxel in phase II studies in patients with cancer J Clin Oncol 16 1998 187 196
24. T. Ishizaki, K. Chiba, and T. Sasaki Antipyrine clearance in patients with Gilbert's syndrome Eur J Clin Pharmacol 27 1984 297 302
25. S. Coverdale, K. Byth, and J. Field Antipyrine clearance and response to interferon treatment in patients with chronic active hepatitis C Hepatology 22 1995 1065 1071
26. F.E. de Jongh, J. Verweij, and W.J. Loos Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure J Clin Oncol 19 2001 3733 3739
27. J.M. Kremer, J. Wilting, and L.H. Janssen Drug binding to human alpha-1-acid glycoprotein in health and disease Pharmacol Rev 40 1988 1 47
28. S. Urien, J. Barre, and C. Morin Docetaxel serum protein binding with high affinity to alpha 1-acid glycoprotein Invest New Drugs 14 1996 147 151